Literature DB >> 26879689

Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population.

Oriano Radillo1, Lorella Pascolo2, Stefano Martelossi1, Sara Dal Bo3, Alessandro Ventura1,3.   

Abstract

BACKGROUND: Fecal calprotectin is a noninvasive marker for bowel diseases and it is high valuable to follow disease activity in Crohn's disease (CD) and ulcerative colitis (UC). In this study, we evaluated the diagnostic performance of the recently introduced immunochromatographic assay CalFast in comparison to the well-known ELISA tests for calprotectin assay to obtain a rapid diagnosis of bowel inflammation in pediatric patients.
METHODS: CalFast was tested in parallel to the classic ELISA tests CalPrest and PhiCal (gold standards for the calprotectin determination) on 148 fecal samples from pediatric subjects including 104 healthy subjects, 29 with CD, and 15 with UC.
RESULTS: In this study, the sensitivity and specificity of CalFast, CalPrest, and PhiCal were 86.4%, 88.6%, and 93.2% and 86.6%, 74%, and 64.4%, respectively. The area under the curve, obtained from receiver operating characteristic analysis, indicated the lack of significant difference among all the kits used.
CONCLUSION: The immunochromatographic assay demonstrated good diagnostic predictive values, comparable to those of the ELISA methods, and may represent a valid alternative in order to save operators' time. The test, in fact, has a short turnaround time and does not need a specific ELISA instrumentation.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  children; fecal marker; gastrointestinal diseases; immunochromatographic assay; immunoenzymatic assay

Mesh:

Substances:

Year:  2016        PMID: 26879689      PMCID: PMC6807198          DOI: 10.1002/jcla.21886

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  27 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

Review 2.  Understanding diagnostic tests 3: Receiver operating characteristic curves.

Authors:  Anthony K Akobeng
Journal:  Acta Paediatr       Date:  2007-03-21       Impact factor: 2.299

3.  Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience.

Authors:  Jeffrey Hyams; James Markowitz; Anthony Otley; Joel Rosh; David Mack; Athos Bousvaros; Subra Kugathasan; M Pfefferkorn; Vasundhara Tolia; Jonathan Evans; William Treem; Robert Wyllie; Robert Rothbaum; J del Rosario; Aubrey Katz; Adam Mezoff; M Oliva-Hemker; Trudy Lerer; Anne Griffiths
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-10       Impact factor: 2.839

4.  Accuracy of four fecal assays in the diagnosis of colitis.

Authors:  Alain M Schoepfer; Michael Trummler; Petra Seeholzer; Dominique H Criblez; Frank Seibold
Journal:  Dis Colon Rectum       Date:  2007-10       Impact factor: 4.585

Review 5.  Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.

Authors:  N Waugh; E Cummins; P Royle; N-B Kandala; D Shyangdan; R Arasaradnam; C Clar; R Johnston
Journal:  Health Technol Assess       Date:  2013-11       Impact factor: 4.014

6.  Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

7.  Appraisal of the pediatric ulcerative colitis activity index (PUCAI).

Authors:  Dan Turner; Jeffrey Hyams; James Markowitz; Trudy Lerer; David R Mack; Jonathan Evans; Marian Pfefferkorn; Joel Rosh; Marsha Kay; Wallace Crandall; David Keljo; Anthony R Otley; Subra Kugathasan; Ryan Carvalho; Maria Oliva-Hemker; Christine Langton; Petar Mamula; Athos Bousvaros; Neal LeLeiko; Anne M Griffiths
Journal:  Inflamm Bowel Dis       Date:  2009-08       Impact factor: 5.325

Review 8.  Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.

Authors:  Taina Sipponen
Journal:  Dig Dis       Date:  2013-11-14       Impact factor: 2.404

9.  The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease.

Authors:  Paul Henderson; Aoife Casey; Sally J Lawrence; Nicholas A Kennedy; Kathleen Kingstone; Pam Rogers; Peter M Gillett; David C Wilson
Journal:  Am J Gastroenterol       Date:  2012-02-28       Impact factor: 10.864

Review 10.  Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.

Authors:  Patrick F van Rheenen; Els Van de Vijver; Vaclav Fidler
Journal:  BMJ       Date:  2010-07-15
View more
  1 in total

1.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.